hainan shuangcheng pharmac-a
(002693:Shenzhen Stock Exchange)
Transactions by HAINAN SHUANGCHENG PHARMAC-A (002693) in the last 6 months
Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) signed a letter of intent to acquire a 74.9% stake in Lyomark Pharma GmbH and 74.9% stake in Bendalis GmbH from Lothar Böning and Helmut Wolf on May 7, 2015. The deal value is in the range of CNY 70 million to CNY 200 million. Lyomark has total assets of CNY 44.79 million (€6.6 million) by the end of 2014. Bendalis had total assets of CNY 19 million (€2.8 million) by the end of 2014. The conversion was done through ...
Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) agreed to acquire a 46% stake in Hangzhou Aoya Biotechnology Co Ltd. from Zhejiang Juke Industrial Co., Ltd. for approximately CNY 510 million on January 31, 2015. In a related deal, Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) agreed to acquire Hangzhou Aopeng Investment for approximately CNY 960 million on February 3, 2015. On February 2, 2015, Hainan Shuangcheng paid a CNY 300 million deposit; ...
Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) entered into framework agreement to acquire Hangzhou Aopeng Investment Management Co., Ltd. from Huang Shaofeng and Zhou Yulan for approximately CNY 960 million on January 31, 2015. Hainan Shuangcheng Pharmaceutical Co., Ltd. will acquire 81% stake from Huang Shaofeng for CNY 779.14 million and 19% stake from Zhou Yulan for CNY 182.76 million. Within 10 days after the private placement proceeds are in place, Hainan ...
Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) announced a private placement of up to 74,318,744 A shares at no less than CNY 12.11 per share for gross proceeds of up to CNY 900,000,000 on January 31, 2015. The transaction will include participation from 10 designated investors. The transaction has been approved in its 18th meeting of the 2nd directorate and 13th meeting of the 2nd supervisory board and is still subject to shareholders' approval and China ...
Hainan Weile Pharmaceutical Co., Ltd. announced that it will receive CNY 19,000,000 in an equity round of funding from existing investor Hainan Shuangcheng Pharmaceutical Co., Ltd. on January 29, 2015. The company announced that the transaction has been approved by the 17th meeting of the 2nd directorate of the investor. Following the transaction, the registered capital of the company will increase from CNY 1,000,000 to CNY 20,000,000.
|No competitor information is available for 002693.|
|View Industry Companies|